Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Direct ...

The enhanced therapeutic effect observed in ctDNA-guided patients supports ctDNA's role as a decision-modifying biomarker for personalization management following neoadjuvant chemoimmunotherapy.

Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

The radically mediated dithiolane-ene copolymerization enables efficient incorporation of dynamic disulfide bonds into vinyl polymers, facilitating control over dynamic disulfide bond integration.

Abstract Purpose To determine whether treatment with TAS-102 can induce circulating tumor DNA (ctDNA) clearance at 6 months and delay/prevent disease recurrence in colorectal cancer (CRC) patients ...

Patients and providers find the Colon Age tool acceptable and useful for individualizing colorectal cancer risk and encouraging earlier screening.

The European Society for Medical Oncology (ESMO) Congress on Gastrointestinal Cancers took place in Barcelona from 2 to 5 July 2025. Over four days, the meeting featured 34 scientific sessions and ...